Literature DB >> 9731555

Human leukocyte antigen-C genes and susceptibility to primary sclerosing cholangitis.

M M Moloney1, L J Thomson, M J Strettell, R Williams, P T Donaldson.   

Abstract

Genetic susceptibility to primary sclerosing cholangitis (PSC) is associated with the extended HLA A1-B8-DR3 haplotype and also with the DRB3*0101-DRB1*0301-DQA1*0103-DQB1*0603 haplotype. However, very few studies have considered the role of HLA C which lies between HLA A and B, is highly polymorphic, and encodes proteins which play an important role in immunoregulation and in disease susceptibility. Traditional assignment of HLA Cw antigens by serology is both inaccurate and unreliable, with a high error rate. The aim of this study was to characterize the distribution of HLA C alleles in a large group of patients with primary sclerosing cholangitis by using a recently developed polymerase chain reaction-based genotyping technique. Ninety-three white adult patients of northern European origin with well characterized PSC and 100 geographically and racially matched controls were studied. HLA C and HLA DRB1 alleles were assigned by polymerase chain reaction-based genotyping, HLA A and B antigens by standard microlymphocytotoxicity test and extended haplotypes were constructed according to known patterns of linkage disequilibrium. The Cw*07 gene was found in 67.7% of patients versus 54% of controls (P = .051, OR = 1.79). This increase was a result of inheritance of the Cw*0701 allele which was found in 51.6% of patients compared with 34% of controls (P = .013, OR = 2.07). There were no significant differences in the frequencies of any of the other Cw alleles including the Cw*07 group: Cw*0702, Cw*0703, and Cw*0704. HLA-encoded genetic susceptibility to PSC is associated with the HLA Cw*0701 allele, but the association is weak and may simply reflect linkage disequilibrium with the HLA B8-DR3 haplotype. These findings indicate that the telomeric limit of HLA-encoded susceptibility to primary sclerosing cholangitis lies close to the HLA C locus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9731555     DOI: 10.1002/hep.510280309

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

Review 1.  Primary sclerosing cholangitis.

Authors:  S A Mitchell; R W Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations.

Authors:  Christopher L Bowlus; Chin-Shang Li; Tom H Karlsen; Benedicte A Lie; Carlo Selmi
Journal:  Liver Transpl       Date:  2010-11       Impact factor: 5.799

Review 3.  Genetic epidemiology of primary sclerosing cholangitis.

Authors:  Tom-H Karlsen; Erik Schrumpf; Kirsten-Muri Boberg
Journal:  World J Gastroenterol       Date:  2007-11-07       Impact factor: 5.742

Review 4.  Update on inflammatory bowel disease in patients with primary sclerosing cholangitis.

Authors:  Christos Tsaitas; Anysia Semertzidou; Emmanouil Sinakos
Journal:  World J Hepatol       Date:  2014-04-27

5.  Autoimmune hepatitis and eosinophilic granulomatosis with polyangiitis: a rare association.

Authors:  Saroj Lohani; Salik Nazir; Niranjan Tachamo; Pavani Pagolu
Journal:  BMJ Case Rep       Date:  2017-01-20

Review 6.  Pathogenesis of primary sclerosing cholangitis.

Authors:  Marion J Pollheimer; Emina Halilbasic; Peter Fickert; Michael Trauner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-12       Impact factor: 3.043

7.  Type 2 Autoimmune Hepatitis in a Male Patient with a Rare Complication of Vasculitis.

Authors:  Ashar Shahid; Avinash Punshi; Bilal Ahmed Khan; Maaz Bin Nazir; Hidayat Ullah
Journal:  Cureus       Date:  2020-03-21

8.  HLA variants related to primary sclerosing cholangitis influence rejection after liver transplantation.

Authors:  Bjarte Fosby; Sigrid Næss; Johannes R Hov; James Traherne; Kirsten M Boberg; John Trowsdale; Aksel Foss; Pål-Dag Line; Andre Franke; Espen Melum; Helge Scott; Tom H Karlsen
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.